 CAMBRIDGE, Mass., Sept. 01, 2021 GLOBE NEWSWIRE -- Foghorn Therapeutics Inc. Nasdaq: FHTX, a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences. 